176 related articles for article (PubMed ID: 12629645)
1. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations.
Durante Mangoni E; Forton DM; Ruggiero G; Karayiannis P
J Med Virol; 2003 May; 70(1):62-73. PubMed ID: 12629645
[TBL] [Abstract][Full Text] [Related]
2. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
[TBL] [Abstract][Full Text] [Related]
3. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
[TBL] [Abstract][Full Text] [Related]
4. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.
Odeberg J; Yun Z; Sönnerborg A; Weiland O; Lundeberg J
J Med Virol; 1998 Sep; 56(1):33-8. PubMed ID: 9700630
[TBL] [Abstract][Full Text] [Related]
5. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.
Polyak SJ; McArdle S; Liu SL; Sullivan DG; Chung M; Hofgärtner WT; Carithers RL; McMahon BJ; Mullins JI; Corey L; Gretch DR
J Virol; 1998 May; 72(5):4288-96. PubMed ID: 9557719
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
[TBL] [Abstract][Full Text] [Related]
7. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV.
Abbate I; Cappiello G; Lo Iacono O; Longo R; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxì A; Solmone MC; Spanò A; Ippolito G; Capobianchi MR
J Biol Regul Homeost Agents; 2003; 17(2):162-5. PubMed ID: 14518716
[TBL] [Abstract][Full Text] [Related]
9. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha.
Gerotto M; Dal Pero F; Sullivan DG; Chemello L; Cavalletto L; Polyak SJ; Pontisso P; Gretch DR; Alberti A
J Viral Hepat; 1999 Sep; 6(5):367-72. PubMed ID: 10607252
[TBL] [Abstract][Full Text] [Related]
10. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
Zhang L; Han F; Zhang D; Dou XG
Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
[TBL] [Abstract][Full Text] [Related]
11. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
12. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
[TBL] [Abstract][Full Text] [Related]
13. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the interferon sensitivity-determining region (ISDR) correlate with the complexity of hypervariable region (HVR)-1 in the Japanese variant of hepatitis C virus (HCV) type 1b.
Nakano I; Fukuda Y; Katano Y; Toyoda H; Hayashi K; Kumada T; Nakano S
J Med Virol; 2004 Sep; 74(1):54-61. PubMed ID: 15258968
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a.
Bagaglio S; Bruno R; Lodrini S; De Mitri MS; Andreone P; Loggi E; Galli L; Lazzarin A; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):153-61. PubMed ID: 14518715
[TBL] [Abstract][Full Text] [Related]
16. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
[TBL] [Abstract][Full Text] [Related]
17. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.
Khorsi H; Castelain S; Wyseur A; Izopet J; Canva V; Rombout A; Capron D; Capron JP; Lunel F; Stuyver L; Duverlie G
J Hepatol; 1997 Jul; 27(1):72-7. PubMed ID: 9252076
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J
J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
20. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
